Hongyun Biotechnology

Established in 2018 and based in Nanjing, China, Hongyun Biotechnology is a biopharmaceutical company that develops clinical-stage small molecule drugs. The company focuses on structural pharmacology and integrates cutting-edge computational technologies such as molecular dynamics simulation, computational chemistry and artificial intelligence to develop new drugs. The company has separate R&D centers in Shanghai and Beijing, and has closed a series B+ funding in May 2023. The company has built a number of small molecule innovative drug development pipelines covering targeted therapeutic areas for tumor resistance, rare diseases and other major diseases with high clinical demand.

Currently, the Company has launched Phase I clinical trial studies for H002, a next-generation EGFR inhibitor developed simultaneously in China and the U. S. , which is an inhibitor for the treatment of multiple non-small cell lung cancers with EGFR activating or drug-resistant mutations. Meanwhile, a first-in-class target program targeting a variety of tumors, including breast cancer, has entered the PCC phase and is expected to be filed in the clinic in 2024.

The company will use the series B+ funding for clinical trials of the Company's next generation EGFR inhibitor, H002, in patients with non-small cell lung cancer.